←
BioMAdvanced Diagnostics225 posts
BioMAdvanced Diagnostics avatar

BioMAdvanced Diagnostics

@BioMAdvanced

#Medtech #DeepTech #Nantes, spinoff from @CR2TI_Nantes @UnivNantes @Inserm | Enabling a personalized medicine by providing unprecedented tools to clinicians

◷ Joined March 2021▧ 123 Photos and videos
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·23 May 2024

This new accolade joins our previous recognitions: - 🏆 2021: Prix de la Région Pays de la Loire at Start West. - 🏆 2022: Award for job creation at Startups & Innovation Day Each award reminds us of all the progress we've made since our launch in 2021.

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·13 Mar 2024

Wondering how we're able to process our clinical trials at such a rapid pace? The secret lies in Bio-collections (or Biobanks). These collections of samples (blood, biopsies, etc.) and clinical data, gathered from patients recruited without bias. #MedTech

Post attachmentPost attachmentPost attachmentPost attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·5 Mar 2024

“BioMAdvanced Diagnostics” and its logo have been successfully registered as Trademarks in the United States of America. Another step in our journey towards delivering great diagnostics solutions to transplanted patients and their clinicians around the world! #medtech #nantes

Post attachmentPost attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·28 Feb 2024

Why does this matter ? Companies involved in the development and manufacturing of Medical Devices are REQUIRED to have a Certified Quality System in accordance with the ISO 13485 standard.

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·21 Feb 2024

These tests were conducted independently on two separate days under the supervision of our team. ▶▶▶We are pleased to announce that the product has met all of our expectations. (5/5)

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·21 Feb 2024

📌In pursuit of this objective, two Medical Biology Engineers from a leading French University Hospital biology lab visited our own molecular biology lab. Without prior knowledge of the product, they conducted tests solely relying on the provided instructions for use. (4/5)

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·21 Feb 2024

This phase is aiming at verifying/validating the user interfaces while taking into account the human factor (essentially checking the ease of use and the safety/risk management). (3/5)

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·21 Feb 2024

As our product development progresses, we are currently immersed in the summative usability assessment of our kidney IVD test, encompassing both the kit and software components. (2/5)

Post attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·14 Feb 2024

We have now converted the option into a tangible reality by signing the definitive license agreement. This move opens a vast market encompassing 25 million patients globally, grappling with cancer or kidney failure and facing the looming threat of irreversible muscular atrophy.

Post attachmentPost attachmentPost attachment
BioMAdvanced Diagnostics avatar
BioMAdvanced Diagnostics@BioMAdvanced·14 Feb 2024

This agreement was an option - 3 additional steps were needed from Clermont Auvergne Innovation for us to confidently move forward. 👏It only took the Clermont teams 6 months to accomplish those 3 steps. This rapid execution and its quality show the teams' remarkable efficiency.